Developer docs
API playgroundTry for free, no card

Search company profiles

Wheeler Bio

Full company profile

uuid0000a2y

Namestring
Wheeler Bio
Legal namestring
Wheeler Bio, Inc.
Websiteurl
wheelerbio.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Wheeler Bio is a privately held biologics contract development and manufacturing organization (CDMO) founded in 2021 and headquartered in Oklahoma City. The company provides antibody-based therapeutic development and manufacturing services spanning cell line development, process and analytical development, cGMP drug substance and drug product manufacturing, and IND regulatory support. Its core platform, ModularCMC™, is a phase-appropriate, modular framework that combines standardized work packages with Quality-by-Design principles, aiming to compress gene-to-clinic timelines to as few as 10 months through fixed-fee work packages. The platform integrates proprietary and licensed technologies including ATUM's Leap-In Transposase system for CHO cell line development and an AI/ML clone selection model developed with the University of Oklahoma that achieves 76.2% accuracy in predicting high-yield cell lines from early-stage growth data.

The company operates a 35,000 sq. ft. cGMP facility with 500L bioreactor scale in downtown Oklahoma City, featuring a Charles River Laboratories-operated RightSourceSM on-site QC laboratory. Wheeler Bio has announced plans for a 52,000 sq. ft. large-scale manufacturing expansion adjacent to a biomanufacturing workforce training center in the OKC Innovation District. Its service offering is extended through strategic partnerships with Alloy Therapeutics (lead optimization), Pharmefex (regulatory), and Pyramid Pharma Services (fill-finish), enabling end-to-end discovery-to-IND program management under a single client interface.

Wheeler Bio generates revenue through project-based, fixed-fee CDMO contracts with emerging biopharma companies developing monoclonal antibodies, bispecifics/multispecifics, fusion proteins, and antibody-drug conjugates. The company has raised approximately $80M across Seed, Series A, and Series A-1 rounds between 2022 and 2025, with Echo Investment Capital and Alloy Therapeutics as consistent co-lead investors. As of late 2025, the company employs 51-100 people and is pursuing geographic expansion into Asia-Pacific through a strategic partnership with Mitsubishi Corporation.

Short descriptiontext

Wheeler Bio is a privately held biologics CDMO that provides antibody-based therapeutic development and cGMP manufacturing services for emerging biopharma clients. Its ModularCMC platform delivers phase-appropriate, fixed-fee work packages compressing gene-to-clinic timelines to as few as 10 months.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOklahoma City, United States
HQ citystring
Oklahoma City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics contract manufacturing, antibody CDMO services, cell line development, cGMP drug substance manufacturing, CMC development services
Industry3 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biologics Contract Development and Manufacturing (CDMO)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1CDMO Development and Manufacturing Services
TypeProfessional Services
Description

Wheeler Bio generates revenue through contract development and manufacturing services for antibody-based therapeutics. Services span cell line development, process and analytical development, non-cGMP and cGMP drug substance manufacturing, drug product manufacturing, and regulatory CMC support. Revenue is project-based with fixed-fee work packages and milestone-based billing.

wheelerbio.com
2Partnered Service Fees
TypeProfessional Services
Description

Fees from integrated partner services including regulatory support (Pharmefex), fill-finish (Pyramid Pharma Services), and lead optimization (Alloy Therapeutics), where Wheeler coordinates and manages delivery as the primary client interface.

wheelerbio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Pricing details3 tiers
1Custom CDMO project pricing — Lead Selection module
ModelOtherBilling cadenceMulti-year contract
Notes

Transfection to top pool selection in as few as 3 months. Fixed-fee work package model with predictable budgets aligned to funding milestones.

wheelerbio.com
2Custom CDMO project pricing — Cell Line Development module
ModelOtherBilling cadenceMulti-year contract
Notes

Transfection to MCB conditional release in as few as 6 months. Fixed-fee work package with milestone-based deliverables.

wheelerbio.com
3Custom CDMO project pricing — Lead to Clinic module
ModelOtherBilling cadenceMulti-year contract
Notes

Transfection to Drug Product release in as few as 10 months. Fixed-fee, predictable scope covering end-to-end CMC development.

wheelerbio.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Portable CMC™
Description

Open-source CMC middleware platform that delivers speed, efficiency, predictability, and freedom to operate by integrating discovery CROs and CDMOs to bridge the translational gap from discovery to IND filing

wheelerbio.com
+1 more record
Core offering1 text field

Wheeler Bio is a biologics contract development and manufacturing organization (CDMO) that provides antibody-based therapeutic development and manufacturing services through its proprietary ModularCMC platform. Services span cell line development, process and analytical development, formulation, master cell banking, non-GMP and cGMP drug substance manufacturing, drug product manufacturing, and integrated regulatory CMC support for emerging biopharma clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Gene to clinic in as few as 10 months (transfection to Drug Product release)
+4 more records
Product overview1 text field

Wheeler Bio is a biologics CDMO (contract development and manufacturing organization) offering a platform-plus-modules architecture centered on its ModularCMC™ platform. ModularCMC™ provides structured, phase-appropriate work packages for antibody-based therapeutics development from discovery through CGMP manufacturing. The platform includes three integrated service modules (Lead Selection, Clone Selection, CDMO Selection) composed of 10 discrete work packages covering stable pool generation, process/analytical/formulation development, single cell cloning, cell banking, drug substance manufacturing, drug product management, and regulatory documentation. Complementary service modules include Cell Line Development, Process Development & Optimization, Analytical Development & Qualification, and Formulation Development. Manufacturing services encompass Master Cell Banking, Drug Substance Manufacturing, and Drug Product Manufacturing. Partnered services extend capabilities through alliances with Alloy Therapeutics (lead optimization), Pharmefex (regulatory support), and Pyramid Pharma Services (fill-finish). The company specializes in therapeutic modalities including monoclonal antibodies (mAbs), multispecifics, fusion proteins, and antibody-drug conjugates (ADCs).

Product and service20 records
1ModularCMC
CategoryCore Platform
Description

A mammalian cell culture-based modular CMC platform for antibody-based therapeutic development that provides structured, phase-appropriate work packages using Quality-by-Design principles, AI/ML-enabled clone selection, and data-driven analytics to derisk development and reduce timelines from discovery to cGMP manufacturing.

2Cell Line Development
CategoryCMC Development Service
Description

Mammalian cell line development services combining advanced expression technologies including Leap-In Transposase with experienced teams integrated into the ModularCMC platform to accelerate the path from discovery to cGMP manufacturing for antibody-based therapeutics.

3Lead Selection Program
CategoryCMC Development Program
Description

Non-clonal cell line development program providing transfection to top pool selection in as few as 3 months; generates representative materials, early product quality assessments, and manufacturability data for early-stage antibody programs.

4Cell Line Development Program
CategoryCMC Development Program
Description

Clonal cell line development program providing transfection to MCB conditional release in as few as 6 months using state-of-the-art expression technologies and automated workflows.

5Rapid Tox Supply
CategoryCMC Development Program
Description

Program providing transfection to SBC-derived toxicology material supply in as few as 3 months for IND-enabling studies.

6Traditional Tox Supply
CategoryCMC Development Program
Description

Program providing transfection to clonally-derived toxicology material supply in as few as 6 months for IND-enabling studies.

7Lead to Clinic Program
CategoryCMC Development Program
Description

Complete program integrating all ModularCMC work packages from transfection to drug product release in as few as 10 months.

8Process Development & Optimization
CategoryCMC Development Service
Description

Data-driven upstream and downstream process development services including seed train optimization, media screening, bioreactor optimization, and purification development to ensure high yield, consistent quality, and efficient scale-up for antibody therapeutics.

9Analytical Development & Qualification
CategoryCMC Development Service
Description

Molecular characterization and phase-appropriate analytical methods designed to deliver IND/CTD-ready insights including structural analysis, potency assays, method qualification, and stability studies for antibody-based therapeutics.

10Formulation Development
CategoryCMC Development Service
Description

Stage-appropriate formulation development customized to the molecule's target product profile, ranging from platform screening for standard monoclonal antibody programs to bespoke development for complex antibody formats.

11Master Cell Banking
CategoryManufacturing Service
Description

cGMP cell banking services establishing well-characterized production cell banks to support reliable biologics manufacturing and clinical drug substance supply.

12Drug Substance Manufacturing
CategoryManufacturing Service
Description

Integrated drug substance manufacturing for antibody therapeutics, providing non-GMP and cGMP production at 500L scale with high-quality, fully traceable material.

13Drug Product Manufacturing
CategoryManufacturing Service
Description

Drug product services from cGMP drug substance release through fill-finish coordination, drug product release testing, and ICH Q1A(R3)-aligned stability studies.

14Lead Optimization (Partnered with Alloy Therapeutics)
CategoryPartnered Service
Description

Partnered service combining Alloy Therapeutics' antibody discovery platforms and lead optimization expertise with Wheeler Bio's ModularCMC approach for a seamless path from discovery to clinical manufacturing.

15IND Regulatory Support (Partnered with Pharmefex)
CategoryPartnered Service
Description

Partnered regulatory service providing integrated IND and regulatory CMC support including CTD Module 3 authoring, submission strategy, and regulatory execution from early development through IND filing.

16Fill-Finish (Partnered with Pyramid Pharma Services)
CategoryPartnered Service
Description

Partnered fill-finish service providing vial, syringe, and cartridge filling for liquid and lyophilized products at clinical to commercial scales, with Wheeler Bio providing High-Touch project management throughout.

17Multispecifics Development
CategoryTherapeutic Modality Service
Description

Integrated, phase-appropriate development and manufacturing support for bispecific and multispecific antibody therapeutics, addressing expression, stability, and product quality considerations.

18ADC Manufacturing
CategoryTherapeutic Modality Service
Description

Antibody-drug conjugate development and manufacturing support including antibody expertise, process development, and analytical characterization aligned with downstream conjugation and manufacturability requirements.

19mAbs Manufacturing & Development
CategoryTherapeutic Modality Service
Description

Monoclonal antibody therapeutics manufacturing and development services for emerging biopharma clients using mammalian CHO cell-based production.

20Fusion Proteins Manufacturing & Development
CategoryTherapeutic Modality Service
Description

Fc fusion protein therapeutics manufacturing and development services using mammalian cell-based production systems.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

Researchers at OU led by Professor Chongle Pan developed a machine learning model in collaboration with Wheeler Bio that predicts high-yield cell lines for monoclonal antibody production with 76.2% accuracy. The model uses the Luedeking-Piret equation to analyze early-stage growth data, addressing a weeks-long bottleneck in the biomanufacturing process. Research was funded by a $35M U.S. EDA program for Oklahoma City's biotechnology sector.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-05-31
Description

Charles River Laboratories operates an on-site RightSourceSM biologics testing laboratory at Wheeler Bio's Oklahoma City cGMP facility. Charles River provides and operates all QC testing infrastructure using their quality management systems, test methods, and SOPs. The RightSourceSM lab began operations in Q3 2023 and started in-process and release testing by Q4 2023.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-11-30
Description

Wheeler Bio licensed ATUM's proprietary Leap-In Transposase and miCHO cell line development technology to incorporate into its cell line development platform. The technology enables semi-targeted gene insertion for highly productive, stable CHO cell lines with an established regulatory track record and rapid speed-to-clinic workflow.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-08-12
Description

Alloy Therapeutics, a Boston-based biotechnology company providing antibody discovery platforms, partnered with Wheeler Bio at founding to create a seamless path from antibody discovery to clinical manufacturing. The partnership combines Alloy's transgenic mouse platforms and lead optimization expertise with Wheeler Bio's ModularCMC approach, providing integrated project management from discovery through manufacturing. Alloy is both a founding strategic partner and an investor in Wheeler Bio.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Wheeler Bio partners with Pharmefex for integrated IND regulatory support, combining deep regulatory expertise with ModularCMC platform data. Services include CTD Module 3 documentation, submission strategy, regulatory execution from early development through IND filing. Pharmefex brings 11 years of experience, 33 consultants, and 5 regulatory approvals.

6Pyramid Pharma Services
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Wheeler Bio partners with Pyramid Pharma Services for seamless fill-finish services including vial, syringe, and cartridge filling; liquid and lyophilized products; and packaging and assembly. Wheeler Bio provides High-Touch project management throughout the fill-finish process, enabling seamless transition from drug substance manufacturing without technology transfer delays.

wheelerbio.com
Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1KBI Biopharma
TypeDirect peer
Description

Mid-sized biologics CDMO focused on mammalian cell line development, process development, and cGMP manufacturing for clinical-stage programs. Direct peer of Wheeler on antibody CDMO services targeting emerging biopharma with similar scale and modality focus.

TypeBroad incumbent
Description

One of the largest biologics CDMOs globally, offering end-to-end antibody discovery-to-commercial services with extensive CHO-based capacity. Direct competitor for Wheeler on antibody CDMO work but with substantially greater scale, though recent U.S. regulatory headwinds may shift competitive dynamics.

TypeBroad incumbent
Description

Large-scale biologics CDMO with mammalian and microbial capabilities across clinical and commercial scales, frequently competing for emerging biopharma programs. Comparable to Wheeler on antibody CDMO services but with significantly larger infrastructure and longer operating history.

TypeDirect peer
Description

U.S.-headquartered biologics CDMO with manufacturing across multiple modalities including antibodies and vaccines, targeting similar emerging biopharma customers. Comparable to Wheeler on mammalian antibody CDMO offerings at overlapping scales.

TypeBroad incumbent
Description

Global biologics CDMO with very large-scale mammalian manufacturing capacity, increasingly focused on emerging biotech CDMO services. Comparable to Wheeler on CHO antibody CDMO offerings but with multi-fold greater bioreactor scale and capacity.

TypeBroad incumbent
Description

Global biologics CDMO offering mammalian and microbial development and manufacturing services for clinical and commercial supply. Comparable to Wheeler on antibody-focused mammalian CDMO services, with broader modality coverage and larger footprint.

TypeBroad incumbent
Description

One of the world's largest biologics CDMOs offering mammalian cell culture development and manufacturing across scales, with global facilities and broad modality coverage. Directly comparable to Wheeler on CHO-based antibody manufacturing but at vastly greater scale and commercial-supply reach.

TypeDirect peer
Description

Oklahoma City-based biologics CDMO offering mammalian cell culture, microbial, and plasmid DNA manufacturing services. Direct geographic and modality peer to Wheeler, with a longer operating history and broader modality mix including microbial biologics.

9Stellar Biologics
TypeEmerging player
Description

Smaller emerging biologics CDMO focused on mammalian cell line development and clinical-stage manufacturing for antibody therapeutics. Comparable to Wheeler on emerging-biopharma-focused antibody CDMO positioning with similar scale.

TypeDirect peer
Description

U.S.-based biologics CDMO providing mammalian cell line development, process development, and GMP manufacturing services for antibody therapeutics. Comparable to Wheeler on emerging-biopharma-focused CHO antibody CDMO services at similar scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wheeler Bio

Biologics Contract Development and Manufacturing (CDMO)wheelerbio.com

Wheeler Bio is a privately held biologics CDMO that provides antibody-based therapeutic development and cGMP manufacturing services for emerging biopharma clients. Its ModularCMC platform delivers phase-appropriate, fixed-fee work packages compressing gene-to-clinic timelines to as few as 10 months.

What Wheeler Bio does

Wheeler Bio is a privately held biologics contract development and manufacturing organization (CDMO) founded in 2021 and headquartered in Oklahoma City. The company provides antibody-based therapeutic development and manufacturing services spanning cell line development, process and analytical development, cGMP drug substance and drug product manufacturing, and IND regulatory support. Its core platform, ModularCMC™, is a phase-appropriate, modular framework that combines standardized work packages with Quality-by-Design principles, aiming to compress gene-to-clinic timelines to as few as 10 months through fixed-fee work packages. The platform integrates proprietary and licensed technologies including ATUM's Leap-In Transposase system for CHO cell line development and an AI/ML clone selection model developed with the University of Oklahoma that achieves 76.2% accuracy in predicting high-yield cell lines from early-stage growth data.

The company operates a 35,000 sq. ft. cGMP facility with 500L bioreactor scale in downtown Oklahoma City, featuring a Charles River Laboratories-operated RightSourceSM on-site QC laboratory. Wheeler Bio has announced plans for a 52,000 sq. ft. large-scale manufacturing expansion adjacent to a biomanufacturing workforce training center in the OKC Innovation District. Its service offering is extended through strategic partnerships with Alloy Therapeutics (lead optimization), Pharmefex (regulatory), and Pyramid Pharma Services (fill-finish), enabling end-to-end discovery-to-IND program management under a single client interface.

Wheeler Bio generates revenue through project-based, fixed-fee CDMO contracts with emerging biopharma companies developing monoclonal antibodies, bispecifics/multispecifics, fusion proteins, and antibody-drug conjugates. The company has raised approximately $80M across Seed, Series A, and Series A-1 rounds between 2022 and 2025, with Echo Investment Capital and Alloy Therapeutics as consistent co-lead investors. As of late 2025, the company employs 51-100 people and is pursuing geographic expansion into Asia-Pacific through a strategic partnership with Mitsubishi Corporation.

Wheeler Bio firmographics

Firmographics
Name
Wheeler Bio
Legal name
Wheeler Bio, Inc.
Website
https://wheelerbio.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Wheeler Bio is a privately held biologics CDMO that provides antibody-based therapeutic development and cGMP manufacturing services for emerging biopharma clients. Its ModularCMC platform delivers phase-appropriate, fixed-fee work packages compressing gene-to-clinic timelines to as few as 10 months.
Ownership category
akta.pro rank

Wheeler Bio industry classification

Industry
Product category
Biologics Contract Development and Manufacturing (CDMO)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Biologics contract manufacturing
  • Antibody CDMO services
  • Cell line development
  • CGMP drug substance manufacturing
  • CMC development services

Where Wheeler Bio is headquartered

Location

Headquarters

HQ city
Oklahoma City
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Wheeler Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. CDMO Development and Manufacturing Services: Wheeler Bio generates revenue through contract development and manufacturing services for antibody-based therapeutics. Services span cell line development, process and analytical development, non-cGMP and cGMP drug substance manufacturing, drug product manufacturing, and regulatory CMC support. Revenue is project-based with fixed-fee work packages and milestone-based billing.
  2. Partnered Service Fees: Fees from integrated partner services including regulatory support (Pharmefex), fill-finish (Pyramid Pharma Services), and lead optimization (Alloy Therapeutics), where Wheeler coordinates and manages delivery as the primary client interface.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom CDMO project pricing — Lead Selection module
OtherMulti-year contractCustom CDMO project pricing — Cell Line Development module
OtherMulti-year contractCustom CDMO project pricing — Lead to Clinic module

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Wheeler Bio product offering

Product offering

Core offering

Wheeler Bio is a biologics contract development and manufacturing organization (CDMO) that provides antibody-based therapeutic development and manufacturing services through its proprietary ModularCMC platform. Services span cell line development, process and analytical development, formulation, master cell banking, non-GMP and cGMP drug substance manufacturing, drug product manufacturing, and integrated regulatory CMC support for emerging biopharma clients.

Product overview

Wheeler Bio is a biologics CDMO (contract development and manufacturing organization) offering a platform-plus-modules architecture centered on its ModularCMC™ platform. ModularCMC™ provides structured, phase-appropriate work packages for antibody-based therapeutics development from discovery through CGMP manufacturing. The platform includes three integrated service modules (Lead Selection, Clone Selection, CDMO Selection) composed of 10 discrete work packages covering stable pool generation, process/analytical/formulation development, single cell cloning, cell banking, drug substance manufacturing, drug product management, and regulatory documentation. Complementary service modules include Cell Line Development, Process Development & Optimization, Analytical Development & Qualification, and Formulation Development. Manufacturing services encompass Master Cell Banking, Drug Substance Manufacturing, and Drug Product Manufacturing. Partnered services extend capabilities through alliances with Alloy Therapeutics (lead optimization), Pharmefex (regulatory support), and Pyramid Pharma Services (fill-finish). The company specializes in therapeutic modalities including monoclonal antibodies (mAbs), multispecifics, fusion proteins, and antibody-drug conjugates (ADCs).

Differentiator

Problem solved

Functional benefit

Brands

  • Portable CMC™: Open-source CMC middleware platform that delivers speed, efficiency, predictability, and freedom to operate by integrating discovery CROs and CDMOs to bridge the translational gap from discovery to IND filing
  • ModularCMC™

Products and services

  • ModularCMC A mammalian cell culture-based modular CMC platform for antibody-based therapeutic development that provides structured, phase-appropriate work packages using Quality-by-Design principles, AI/ML-enabled clone selection, and data-driven analytics to derisk development and reduce timelines from discovery to cGMP manufacturing.
  • Cell Line Development Mammalian cell line development services combining advanced expression technologies including Leap-In Transposase with experienced teams integrated into the ModularCMC platform to accelerate the path from discovery to cGMP manufacturing for antibody-based therapeutics.
  • Lead Selection Program Non-clonal cell line development program providing transfection to top pool selection in as few as 3 months; generates representative materials, early product quality assessments, and manufacturability data for early-stage antibody programs.
  • Cell Line Development Program Clonal cell line development program providing transfection to MCB conditional release in as few as 6 months using state-of-the-art expression technologies and automated workflows.
  • Rapid Tox Supply Program providing transfection to SBC-derived toxicology material supply in as few as 3 months for IND-enabling studies.
  • Traditional Tox Supply Program providing transfection to clonally-derived toxicology material supply in as few as 6 months for IND-enabling studies.
  • Lead to Clinic Program Complete program integrating all ModularCMC work packages from transfection to drug product release in as few as 10 months.
  • Process Development & Optimization Data-driven upstream and downstream process development services including seed train optimization, media screening, bioreactor optimization, and purification development to ensure high yield, consistent quality, and efficient scale-up for antibody therapeutics.
  • Analytical Development & Qualification Molecular characterization and phase-appropriate analytical methods designed to deliver IND/CTD-ready insights including structural analysis, potency assays, method qualification, and stability studies for antibody-based therapeutics.
  • Formulation Development Stage-appropriate formulation development customized to the molecule's target product profile, ranging from platform screening for standard monoclonal antibody programs to bespoke development for complex antibody formats.
  • Master Cell Banking cGMP cell banking services establishing well-characterized production cell banks to support reliable biologics manufacturing and clinical drug substance supply.
  • Drug Substance Manufacturing Integrated drug substance manufacturing for antibody therapeutics, providing non-GMP and cGMP production at 500L scale with high-quality, fully traceable material.
  • Drug Product Manufacturing Drug product services from cGMP drug substance release through fill-finish coordination, drug product release testing, and ICH Q1A(R3)-aligned stability studies.
  • Lead Optimization (Partnered with Alloy Therapeutics) Partnered service combining Alloy Therapeutics' antibody discovery platforms and lead optimization expertise with Wheeler Bio's ModularCMC approach for a seamless path from discovery to clinical manufacturing.
  • IND Regulatory Support (Partnered with Pharmefex) Partnered regulatory service providing integrated IND and regulatory CMC support including CTD Module 3 authoring, submission strategy, and regulatory execution from early development through IND filing.
  • Fill-Finish (Partnered with Pyramid Pharma Services) Partnered fill-finish service providing vial, syringe, and cartridge filling for liquid and lyophilized products at clinical to commercial scales, with Wheeler Bio providing High-Touch project management throughout.
  • Multispecifics Development Integrated, phase-appropriate development and manufacturing support for bispecific and multispecific antibody therapeutics, addressing expression, stability, and product quality considerations.
  • ADC Manufacturing Antibody-drug conjugate development and manufacturing support including antibody expertise, process development, and analytical characterization aligned with downstream conjugation and manufacturability requirements.
  • mAbs Manufacturing & Development Monoclonal antibody therapeutics manufacturing and development services for emerging biopharma clients using mammalian CHO cell-based production.
  • Fusion Proteins Manufacturing & Development Fc fusion protein therapeutics manufacturing and development services using mammalian cell-based production systems.

Quantifiable outcome

  • Gene to clinic in as few as 10 months (transfection to Drug Product release)
  • +4 more outcomes

Companies that use Wheeler Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Wheeler Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Wheeler Bio partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered strategic, core and flagship.

  • University of OklahomastrategicStrategic or Co-development Partner · 10 February 2026Researchers at OU led by Professor Chongle Pan developed a machine learning model in collaboration with Wheeler Bio that predicts high-yield cell lines for monoclonal antibody production with 76.2% accuracy. The model uses the Luedeking-Piret equation to analyze early-stage growth data, addressing a weeks-long bottleneck in the biomanufacturing process. Research was funded by a $35M U.S. EDA program for Oklahoma City's biotechnology sector.
  • Charles River LaboratoriescoreTechnology or Integration · 31 May 2023Charles River Laboratories operates an on-site RightSourceSM biologics testing laboratory at Wheeler Bio's Oklahoma City cGMP facility. Charles River provides and operates all QC testing infrastructure using their quality management systems, test methods, and SOPs. The RightSourceSM lab began operations in Q3 2023 and started in-process and release testing by Q4 2023.
  • ATUMcoreOEM/ Whitelabel/ Licensing Partner · 30 November 2022Wheeler Bio licensed ATUM's proprietary Leap-In Transposase and miCHO cell line development technology to incorporate into its cell line development platform. The technology enables semi-targeted gene insertion for highly productive, stable CHO cell lines with an established regulatory track record and rapid speed-to-clinic workflow.
  • Alloy TherapeuticsflagshipStrategic or Co-development Partner · 12 August 2022Alloy Therapeutics, a Boston-based biotechnology company providing antibody discovery platforms, partnered with Wheeler Bio at founding to create a seamless path from antibody discovery to clinical manufacturing. The partnership combines Alloy's transgenic mouse platforms and lead optimization expertise with Wheeler Bio's ModularCMC approach, providing integrated project management from discovery through manufacturing. Alloy is both a founding strategic partner and an investor in Wheeler Bio.
  • PharmefexcoreImplementation/ SI/ Consulting PartnerWheeler Bio partners with Pharmefex for integrated IND regulatory support, combining deep regulatory expertise with ModularCMC platform data. Services include CTD Module 3 documentation, submission strategy, regulatory execution from early development through IND filing. Pharmefex brings 11 years of experience, 33 consultants, and 5 regulatory approvals.
  • Pyramid Pharma ServicescoreChannel Partner/ Reseller/ DistributorWheeler Bio partners with Pyramid Pharma Services for seamless fill-finish services including vial, syringe, and cartridge filling; liquid and lyophilized products; and packaging and assembly. Wheeler Bio provides High-Touch project management throughout the fill-finish process, enabling seamless transition from drug substance manufacturing without technology transfer delays.

Scale indicators8 records

Recent moves11 records

Expansion highlights5 records

Wheeler Bio competitors and assessment

Company assessment

Direct peers

  • KBI Biopharma: Mid-sized biologics CDMO focused on mammalian cell line development, process development, and cGMP manufacturing for clinical-stage programs. Direct peer of Wheeler on antibody CDMO services targeting emerging biopharma with similar scale and modality focus.
  • Resilience: U.S.-headquartered biologics CDMO with manufacturing across multiple modalities including antibodies and vaccines, targeting similar emerging biopharma customers. Comparable to Wheeler on mammalian antibody CDMO offerings at overlapping scales.
  • Cytovance Biologics: Oklahoma City-based biologics CDMO offering mammalian cell culture, microbial, and plasmid DNA manufacturing services. Direct geographic and modality peer to Wheeler, with a longer operating history and broader modality mix including microbial biologics.
  • Bionova Scientific: U.S.-based biologics CDMO providing mammalian cell line development, process development, and GMP manufacturing services for antibody therapeutics. Comparable to Wheeler on emerging-biopharma-focused CHO antibody CDMO services at similar scale.

Broad incumbents

  • WuXi Biologics: One of the largest biologics CDMOs globally, offering end-to-end antibody discovery-to-commercial services with extensive CHO-based capacity. Direct competitor for Wheeler on antibody CDMO work but with substantially greater scale, though recent U.S. regulatory headwinds may shift competitive dynamics.
  • Fujifilm Diosynth Biotechnologies: Large-scale biologics CDMO with mammalian and microbial capabilities across clinical and commercial scales, frequently competing for emerging biopharma programs. Comparable to Wheeler on antibody CDMO services but with significantly larger infrastructure and longer operating history.
  • Samsung Biologics: Global biologics CDMO with very large-scale mammalian manufacturing capacity, increasingly focused on emerging biotech CDMO services. Comparable to Wheeler on CHO antibody CDMO offerings but with multi-fold greater bioreactor scale and capacity.
  • AGC Biologics: Global biologics CDMO offering mammalian and microbial development and manufacturing services for clinical and commercial supply. Comparable to Wheeler on antibody-focused mammalian CDMO services, with broader modality coverage and larger footprint.
  • Lonza Biologics: One of the world's largest biologics CDMOs offering mammalian cell culture development and manufacturing across scales, with global facilities and broad modality coverage. Directly comparable to Wheeler on CHO-based antibody manufacturing but at vastly greater scale and commercial-supply reach.

Emerging players

  • Stellar Biologics: Smaller emerging biologics CDMO focused on mammalian cell line development and clinical-stage manufacturing for antibody therapeutics. Comparable to Wheeler on emerging-biopharma-focused antibody CDMO positioning with similar scale.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Wheeler Bio social profiles

Digital presence

Wheeler Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wheeler Bio leadership team

Management profile

Number of profiles

Profiles19 records

Wheeler Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wheeler Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wheeler Bio

What does Wheeler Bio do?

Wheeler Bio is a biologics contract development and manufacturing organization (CDMO) that provides antibody-based therapeutic development and manufacturing services through its proprietary ModularCMC platform. Services span cell line development, process and analytical development, formulation, master cell banking, non-GMP and cGMP drug substance manufacturing, drug product manufacturing, and integrated regulatory CMC support for emerging biopharma clients.

Is Wheeler Bio a public or private company?

Wheeler Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Wheeler Bio founded?

Wheeler Bio was founded in 2021. It employs 51 to 100 people.

Where is Wheeler Bio based?

Wheeler Bio is headquartered in Oklahoma City, United States, in the North America region.

How does Wheeler Bio make money?

Two revenue lines are on record. CDMO Development and Manufacturing Services are the primary driver. The others are partnered Service Fees.

Who are Wheeler Bio's main competitors?

Direct peers on record are KBI Biopharma, Resilience, Cytovance Biologics and Bionova Scientific. Broad incumbents are WuXi Biologics, Fujifilm Diosynth Biotechnologies, Samsung Biologics, AGC Biologics and Lonza Biologics. Stellar Biologics is listed as an emerging player.

Does Wheeler Bio have an API?

No public API is recorded for Wheeler Bio.

What industry is Wheeler Bio in?

Wheeler Bio's product category is Biologics Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireWheeler Bio Appoints Rajesh Beri, Ph.D., as Chief Development OfficerWheeler Bio, Inc., a biologics contract development and manufacturing organization (CDMO), announced the appointment of Rajesh Beri, Ph.D., as Chief Development Officer. Dr. Beri brings over 30 years of biotechnology industry experience, having led more than 70 biologics programs across multiple therapeutic modalities from preclinical research through commercial manufacturing. The appointment strengthens Wheeler Bio's executive leadership team and its ModularCMC platform as the company invests in scientific expertise and manufacturing capacity to meet growing demand for U.S.-based biologics manufacturing.PR NewswireWheeler Bio Launches New Website Reflecting Expansion of Capabilities, Clients Served, and a Commitment to High-Science, High-Touch Biologics ManufacturingWheeler Bio, an Oklahoma-based contract development and manufacturing organization (CDMO) specializing in antibody-based therapeutics, has launched a redesigned website reflecting its evolution into a fully integrated CDMO supporting programs from cell line development through cGMP manufacturing. The new site showcases the company's AI/ML-enabled ModularCMC™ platform, a structured approach to antibody-based development that combines standardized work packages, Quality-by-Design principles, and process development strategies designed to streamline CMC execution and reduce development timelines. The announcement reinforces Wheeler Bio's high-science, high-touch philosophy focused on deep scientific expertise, transparent communication, and partnership-focused project management.Mirage NewsOU, Industry Team Use AI to Speed Antibody Drug OutputUniversity of Oklahoma researchers published a study in Communications Engineering detailing a machine learning model that dramatically accelerates monoclonal antibody manufacturing by predicting cell line productivity from early growth data. The model achieved 76.2% accuracy in selecting higher-performing clones and accurately forecasted daily production trajectories using data from only the first nine days, addressing a weeks-long bottleneck in the biomanufacturing process. The research, conducted in partnership with Oklahoma City-based contract manufacturer Wheeler Bio, was funded through a $35 million U.S. Economic Development Administration program to expand the regional biotechnology industry cluster.YahooA Look at Mitsubishi (TSE:8058) Valuation Following Strategic Biotech Deal with Wheeler BioMitsubishi announced a strategic partnership with Wheeler Bio to expand commercial opportunities in Asia-Pacific, including a direct investment in Wheeler's latest funding round. The company's stock has risen 22.6% in the past three months, but a fair-value analysis rates it overvalued at ¥3,405.PR NewswireWheeler Bio Announces Strategic Partnership with Mitsubishi Corporation to Accelerate Asia-Pacific Business DevelopmentWheeler Bio, a U.S.-based contract development and biomanufacturing organization, announced a strategic partnership with Mitsubishi Corporation to serve as its exclusive commercialization partner across the Asia-Pacific region. Mitsubishi Corporation will invest in Wheeler Bio's Series A-1 financing and leverage its regional network to identify biotech innovators in Japan, South Korea, India, Singapore, Taiwan, and China seeking U.S. development and cGMP manufacturing capabilities. The partnership aims to connect Asia-Pacific biologics companies to Wheeler Bio's AI/ML-enabled ModularCMC platform and cGMP biomanufacturing facility in Oklahoma City.PR NewswireWheeler Bio and MindImmune Therapeutics Sign CDMO Partnership Agreement to Support MindImmune's Lead Alzheimer's Prevention Program, MITI-101Wheeler Bio and MindImmune Therapeutics signed a CDMO partnership agreement to support MindImmune's lead Alzheimer's prevention program, MITI-101. Wheeler Bio will provide integrated process development and cGMP drug substance manufacturing via its ModularCMC platform. MITI-101 is a monoclonal antibody targeting CD11c+ immune cell recruitment into the brain.SecSEC FORM DWheeler Bio, Inc. filed a Form D with the SEC to announce an exempt securities offering under Rule 506(b) with a total offering amount of approximately $36.5 million. The filing indicates that $23.1 million has already been sold to 18 investors as of March 4, 2025, with proceeds designated for general corporate purposes.citybizWheeler Bio Raises $35M Series A-1 FundingWheeler Bio, a biopharmaceutical contract development and manufacturing organization, raised $35 million in Series A-1 funding. The round was led by Alloy Therapeutics and Echo Investment Capital, with participation from Mitsubishi Corporation (Americas), Germin8 Ventures, and Russell Westbrook Enterprises.Business Wire BlogWheeler Bio Announces Oversubscribed $35M Series, Plans for Expansion and Continued GrowthWheeler Bio closed an oversubscribed $35 million Series A-1 financing round led by Alloy Therapeutics and Echo Investment Capital. The funding will expand its partner base, team, and capabilities, including a planned 52,000-square-foot biologics manufacturing facility in Oklahoma City.WheelerbioRethinking the Conventional CDMO ModelThe article argues that traditional Contract Development and Manufacturing Organization (CDMO) models are becoming obsolete due to rising drug complexity and cost pressures, advocating for a shift toward flexible, strategic partnerships. It highlights Wheeler Bio's Portable CMC platform as a pioneering solution designed to bridge the gap between discovery and clinical manufacturing by integrating digital automation and aligned financial incentives. This new paradigm aims to reduce development timelines and costs while supporting smaller biotech firms in advancing rare disease and personalized medicine therapies.